['colitis, ulcerative']
['high dose', 'low dose', 'placebo']

        Inclusion Criteria:

          1. Male or female, age ≥18 and <75 years, suffering from UC for at least 6 months prior
             to screening

          2. Female patients must be postmenopausal, sterile, or have a negative urine pregnancy
             test prior to entering the study and use adequate contraception during the study if of
             childbearing potential.

          3. Diagnosis of active UC with UCDAI ≥4 and ≤10, with endoscopy score of ≥1 in the UCDAI
             mucosal appearance subscore

        Exclusion Criteria:

          1. Patients diagnosed with Crohn's disease, indeterminate colitis, or ischemic colitis

          2. Female patients who are pregnant or breastfeeding

          3. Ulcerative proctitis with ≤15 cm of disease

          4. Patients with infectious colitis as determined by assessment for Clostridium difficile
             (C. difficile) and fecal pathogens at screening or treatment for C. difficile within
             30 days prior to screening

          5. History of or current evidence of toxic megacolon, fulminant colitis (e.g., Lichtiger
             score of ≥10), colonic perforation
      